JavaScript is disabled. Please enable to continue!
Francais
Print Page

Save this page as a PDF

Mobile search icon
Menu
Cannabis Testing and Consulting >> Cannabis Testing Services >> Cannabis Vision 2021 - 23
Search >>

Cannabis Vision 2021-23: A discussion with Sohil Mana

Sidebar Image

 

Recently, Health Canada kicked off their Cannabis Vision forward outlining their Regulatory Plans and Priorities for 2021-23, focusing on two key areas under the Cannabis Act:

  1. Amendments to the Cannabis Research & Testing Regulations
  2. Amendments to the Cannabis Regulations on Flavors in Cannabis Extracts

Eurofins Experchem Laboratories Inc, the leading service provider in Cannabis Regulatory & Quality Consulting, views these regulatory changes, as a clear roadmap for the Cannabis Industry and greater opportunities for LPs to expand. Let’s hear more from our President, Sohil Mana, and his perspective on these proposed changes.

 

Q: Being a leader in this industry for over 20 years, how do you see these recent changes from Health Canada will impact the LPs and shape the future of the Cannabis Industry?

SM:  Being at the forefront of Cannabis testing for almost a decade, I see this recent change as a positive move by Health Canada, which provides the opportunity for an evidence-based robust path to shape the future of this billion-dollar Industry.

 

Q: Do you think that the amendment to the Cannabis Research & Testing Regulations on non-therapeutic research will create more investment opportunities in Canada from the International level and foster research collaboration with the US?

SM: I think these amendments will create more investment opportunities from local LPs and research partners from the US in the recreational side within a legal R&D licensing framework. In addition, LPs will be able to assess the benefits of non-therapeutic research with human participants.

 

Q: What is the key take-away from these regulatory changes that you would like to share with the LPs?

SM: I think these changes have paved a clear pathway for non-therapeutic cannabis products to enter the market.  The ability to use credible data and an evidence-based approach will fasten up the approval process. Health Canada has fostered research partnership projects by issuing over 400 research licenses in efforts to widen the scope of R&D.